Relationship between non-alcoholic fatty liver disease and inflammation in patients with non-alcoholic fatty liver

Foroughi, Mahnoosh; Maghsoudi, Zahra; Khayyatzadeh, Saeid; Ghiasvand, Reza; Askari, Gholamreza; Iraj, Bijan

doi:10.4103/2277-9175.176368

Cited by 57 publications

(23 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Suggested mechanisms resulting in increased hemoglobin levels are hepatic hypoxia, oxidative stress, formation of reactive oxygen species and lipid peroxidation[ 37 , 39 ]. The association of (subclinical) elevated inflammatory markers and the presence of NAFLD has also been reported in other studies[ 40 ]. This may be explained by increased visceral adipose tissue conferring a pro-inflammatory state[ 41 , 42 ].…”

Section: Discussionsupporting

confidence: 74%

Prevalence and determinants of non-alcoholic fatty liver disease in lifelines: A large Dutch population cohort

et al. 2017

View full text Add to dashboard Cite

Background & aimsNon-alcoholic fatty liver disease is an increasing health issue that develops rather unnoticed with obesity, type 2 diabetes mellitus and metabolic syndrome. We investigated prevalence, determinants and associated metabolic abnormalities of non-alcoholic fatty liver disease in the largest population-based cohort to date.MethodsBiochemical characteristics, type 2 diabetes mellitus and metabolic syndrome were determined in the Lifelines Cohort Study (N = 167,729), a population-based cohort in the North of the Netherlands. Non-alcoholic fatty liver disease was defined as Fatty Liver Index (FLI)≥60. Exclusion criteria were age <18 years, immigrants, missing data to assess FLI and metabolic syndrome, excessive alcohol use, previous-diagnosed hepatitis or cirrhosis and non-fasting blood sampling.ResultsOut of 37,496 included participants (median age 44 years, 62.1% female), 8,259 (22.0%) had a FLI≥60. Individuals with a FLI≥60 were more often male, older, obese, had higher levels of hemoglobinA1c, fasting glucose, liver enzymes, total cholesterol, low-density lipoprotein cholesterol, triglycerides, c-reactive protein and leucocytes and lower high-density lipoprotein cholesterol (all P<0.0001). Participants with a FLI≥60 showed higher prevalence of type 2 diabetes mellitus (9.3% vs. 1.4%), metabolic syndrome (54.2% vs. 6.2%), impaired renal function (20.1% vs. 8.7%) and cardiovascular disease (4.6% vs. 1.6%) (all P<0.0001). Multivariable logistic analysis showed that smoking, hemoglobin, leucocytes, c-reactive protein, platelets, alanine aminotransferase, alkaline phosphatase, albumin, impaired renal function (OR 1.27, 95%CI 1.15–1.41), metabolic syndrome (OR 11.89, 95%CI 11.03–12.82) and its individual components hyperglycemia (OR 2.53, 95%CI 2.34–2.72), hypertension (OR 1.89, 95%CI 1.77–2.01) and reduced high-density lipoprotein cholesterol (OR 3.44, 95%CI 3.22–3.68) were independently associated with suspected non-alcoholic fatty liver disease (all P<0.0001).ConclusionTwenty-two percent (22.0%) of the population in the North of the Netherlands is suspected to suffer from non-alcoholic fatty liver disease, coinciding with a significant increased risk of type 2 diabetes mellitus, metabolic syndrome, cardiovascular disease and impaired renal function.

show abstract

Section: Discussionsupporting

confidence: 74%

Prevalence and determinants of non-alcoholic fatty liver disease in lifelines: A large Dutch population cohort

et al. 2017

View full text Add to dashboard Cite

show abstract

“…In our study, subjects in the NAFLD group presented with signi cantly higher CRP levels. This nding is consistent with the results reported from earlier studies where a positive correlation been CRP and NAFLD have been demonstrated [27]. Furthermore, subjects in the NAFLD group had higher Charlson comorbidity index scores, lower albumin levels and higher GGT levels which are all predictors of short-term and longterm mortality [16,28,29].…”

Section: Discussionsupporting

confidence: 92%

Nonalcoholic fatty liver disease as a risk factor for severity of acute cholangitis

Mahmud

Fteiha

Nubani

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Nonalcoholic fatty liver disease (NAFLD) is one of the most prevalent chronic liver disorders worldwide. Acute cholangitis (AC) is a serious and life-threatening illness. We aimed to determine whether NAFLD is a risk factor for severity of AC.Methods: We retrospectively studied hospitalized patients with diagnosis of AC over the span of 5 years. Subjects were divided into a NAFLD group and Non NAFLD group. We compared between the two groups in terms of demographic characteristics, comorbidities, laboratory data, and severity of AC (including Charlson Comorbidity index and Tokyo Consensus meeting criteria). Results: 298 of 419 patients who had AC and were hospitalized met the inclusion criteria and were included in the study. Of them, 73/298 (24.5%) were included in NAFLD group. NAFLD group patients were younger, diabetic and more obese than non NAFLD group. Subjects in the NAFLD presented with higher serum C-reactive protein and higher liver enzymes (p<0.05, for each parameter) and suffered more events of organ dysfunction(p<0.001) and bacteremia (p<0.005). Regarding the severity of AC according to Tokyo classification, among the NAFLD group more subjects presented with Grade II (39.7 Vs 33.3%, p <0.001) and Grade III (23.3 vs 18.3, p<0.001) cholangitis, as opposed more Grade I cholangitis among the non-NAFLD group (48.4 vs 37%, p<0.001). Multivariate logistic regression analysis showed that NAFLD is independently associated with severe AC, grade III (OR 3.25, 95% CI 1.65-6.45, p=0.038). Conclusions: NAFLD is as an independent risk factor for severity of AC.

show abstract

“…In addition, high level of CRP was also used for the prediction of metabolic syndrome, T2DM, and coronary heart disease [46,47]. Despite the controversial opinions, there are still several studies identified the association between high levels of CRP and NAFLD [48][49][50]. In this study, liraglutide was more effective than metformin at decreasing the levels of CRP.…”

Section: Discussionmentioning

confidence: 78%

Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease

Tian

Zhang

et al. 2018

Bioscience Reports

View full text Add to dashboard Cite

Type 2 diabetes mellitus (T2DM) complicated with non-alcoholic fatty liver disease (NAFLD) is difficult to treat. The present study explored the efficacy of (liraglutide) Lira in treating T2DM complicated with NAFLD. A total of 127 patients suffering from T2DM complicated with NAFLD were enrolled in the present study, and randomly assigned to a Lira group (liraglutide injection: 0.6–1.2 mg/day, 12 weeks, n=52) or a Metformin (Met) group (oral metformin: 1000–1500 mg/day, 12 weeks, n=75). During the treatment phase, the values for fasting plasma glucose (FPG), 2 h plasma glucose (2hPG), glycated hemoglobin (HbA1c), aspartate aminotransferase (AST)/alanine aminotransferase (ALT), and adiponectin (APN) decreased in both the Lira and Met groups, and the levels of Δ2hPG, ΔAST/ALT, and ΔAPN in the Lira group were significantly lower than those in the Met group. The values for total cholesterol (TC), triglycerides (TG), low-and high-density lipoproteins (LDL and HDL), ALT, AST, weight, body mass index (BMI), waist to hip ratio (WHR), and C-reactive protein were markedly increased in both groups, and levels of ΔAST, ΔALT, Δweight, ΔBMI, ΔWHR, and ΔCRP (C-reactive protein) in the Lira group were significantly higher than those in the Met group. An analysis of treatment efficacy showed that liraglutide was better than metformin in its ability to significantly decrease the ALT levels in patients with combined T2DM and NAFLD. Furthermore, liraglutide was more effective than metformin at ameliorating the severity of T2DM complicated with NAFLD, and produced its effects by alleviating liver inflammation and improving liver function.

show abstract

Relationship between non-alcoholic fatty liver disease and inflammation in patients with non-alcoholic fatty liver

Cited by 57 publications

References 28 publications

Prevalence and determinants of non-alcoholic fatty liver disease in lifelines: A large Dutch population cohort

Prevalence and determinants of non-alcoholic fatty liver disease in lifelines: A large Dutch population cohort

Nonalcoholic fatty liver disease as a risk factor for severity of acute cholangitis

Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease

Contact Info

Product

Resources

About